dennis mccain
  • Home
  • Investing
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options

Best Ideas This Week

These companies are estimated to have a very nice one year total return on investment.

Home

Best Ideas 24 September 2017

9/24/2017

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.
(Summary) (Company) (Chart)
24 September 2017
Price $26.62
1yr Target $23.67
Analysts 3
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain -11.20%
Yield 0.00%
1yr Tot Return -11.20%

P/E ---
PEG ---
Beta ---


EPS (ttm) $-4.36
EPS next yr $-1.02
Forward P/E ---
EPS next 5yr 71.00%
1yr Price Support ---

Market Cap $1.76 Bil
Revenues $23.70 Mil
Earnings $-125.90 Mil
Profit Margin ---

Quick Ratio 1.80
Current Ratio 1.80
Debt/Equity ---


1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA ---
ROE ---


Splunk Inc. provides software solutions that enable organizations to gain real-time operational intelligence in the United States and internationally. The company's products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source. It offers Splunk Enterprise, a machine data platform with collection, indexing, search, reporting, analysis, alerting, monitoring, and data management capabilities; and Splunk Cloud service. The company also provides Splunk Light, which offers log search and analysis for small IT environments; and Splunk Analytics for Hadoop, a software for exploring, analyzing, and visualizing data stored in Hadoop and Amazon S3. In addition, it offers Splunk Enterprise Security, which addresses emerging security threats; Splunk User Behavior Analytics that detects cyber-attacks and insider threats; and Splunk IT Service Intelligence, which monitors health and key performance indicators of critical IT services, as well as Splunk App for AWS to ensure cloud security and compliance; Splunk Stream to capture, analyze, and correlate network wire data; and DB Connect to get enterprise context; Palo Alto Networks App for Splunk to gain visibility to Palo Alto Networks firewalls; and Splunk App for Salesforce. Further, the company operates Splunkbase and Splunk Answers Websites, which provide an environment to share apps, collaborate on the use of its software, and provide community-based support, as well as offers application programming interfaces and software development kits. Additionally, it offers maintenance and customer support, training, and consulting and implementation services. The company serves cloud and online services, education, financial services, government, healthcare/pharmaceuticals, industrials/manufacturing, media/entertainment, retail/ecommerce, technology, and telecommunications industries. Splunk Inc. was incorporated in 2003 and is headquartered in San Francisco, California.
(Summary) (Company) (Chart)
24 September 2017
Price $69.53
1yr Target $74.64
Analysts 38
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 7.34%
Yield 0.00%
1yr Tot Return 7.34%

P/E ---
PEG ---
Beta 2.15
​
EPS (ttm) $-2.57
EPS next yr $0.82
Forward P/E 85.21
EPS next 5yr 51.67%
1yr Price Support $42.36

Market Cap $9.84 Bil
Revenues $1.07 Bil
Earnings $-351.10 Mil
Profit Margin ---

Quick Ratio 2.00
Current Ratio 2.00
Debt/Equity 0.00
1yr RevGR 42.11%
3yr RevGR 45.86%
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -21.10%
ROE -44.60%
Pure Storage, Inc. engages in building a data platform that enables businesses to enhance performance and reduce complexity and costs worldwide. The company delivers its data platform through Purity Operating Environment, an optimized software for solid-state memory that offers enterprise-class storage and protocol services; FlashArray and FlashBlade optimized hardware products for solid-state memory to enhance the performance and density of flash, optimize its advanced software services, and reduce solution cost for customers; Pure1, a cloud-based management and support software; and FlashStack, a converged infrastructure solution. Its data platform is used for a range of storage use cases, including database applications, large-scale analytics, private and public cloud infrastructure, Webscale applications, virtual server infrastructure, and virtual desktop infrastructure; and helps customers scale their businesses through real-time and accurate analytics, increase employee productivity, improve operational efficiency, and deliver compelling user experiences to their customers and partners. The company serves large and mid-size organizations across various industries, such as cloud-based software and service providers, consumer Web, education, energy, financial services, government, healthcare, manufacturing, media, retail, and telecommunications through a network of distribution and channel partners. The company was formerly known as OS76, Inc. and changed its name to Pure Storage, Inc. in 2010. Pure Storage, Inc. was founded in 2009 and is headquartered in Mountain View, California.
(Summary) (Company) (Chart)
24 September 2017
Price $15.64
1yr Target $15.75
Analysts 18
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 0.70%
Yield 0.00%
1yr Tot Return 0.70%

P/E ---
PEG ---
Beta ---
​
EPS (ttm) $-1.24
EPS next yr $0.03
Forward P/E 504.52
EPS next 5yr 40.00%
1yr Price Support $1.20

Market Cap $3.29 Bil
Revenues $831.90 Bil
Earnings $-245.80 Mil
Profit Margin ---

Quick Ratio 2.60
Current Ratio 2.70
Debt/Equity 0.00
1yr RevGR 65.32%
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -28.00%
ROE -52.70%
0 Comments

Best Ideas 17 September 2017

9/17/2017

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
NVIDIA Corporation operates as a visual computing company worldwide. It operates in two segments, GPU and Tegra Processor. The GPU segment offers processors, which include GeForce for PC gaming; GeForce NOW for cloud-based game-streaming service; Quadro for design professionals working in computer-aided design, video editing, special effects, and other creative applications; Tesla for deep learning, accelerated computing, and general purpose computing; and GRID for cloud-based visual computing users. The Tegra Processor segment provides processors that integrate a computer onto a single chip under the Tegra brand name; DRIVE automotive computers, which offer self-driving capabilities; and tablet and portable devices for mobile gaming and TV streaming under the SHIELD name. The company's products are used in gaming, professional visualization, datacenter, and automotive markets. It sells its products primarily to original equipment manufacturers, original device manufacturers, system builders, motherboard manufacturers, add-in board manufacturers, and retailers/distributors. NVIDIA Corporation was founded in 1993 and is headquartered in Santa Clara, California.
​(Summary) (Company) (Chart)
17 September 2017
Price $189.11
1yr Target $156.05
Analysts 32
Dividend $0.56
Payout Ratio %

1yr Cap Gain %
Yield %
1yr Tot Return %

P/E 51.56
PEG 3.99
Beta 1.27
​

EPS (ttm) $3.49
EPS next yr $3.95
Forward P/E 45.66
EPS next 5yr 12.92%
1yr Price Support $

Market Cap $109.97 Bil
Revenues $8.34 Bil
Earnings $2.29 Bil
Profit Margin %

Quick Ratio 7.00
Current Ratio 7.80
Debt/Equity 0.35
1yr RevGR 37.92%
3yr RevGR 18.51%
5yr RevGR 11.57%

1yr EarnGR 137.96%
3yr EarnGR 50.81%
5yr EarnGR 22.28%

1yr DivGR 20.00%
3yr DivGR 16.62%
5yr DivGR ---

ROA 23.90%
ROE 39.40%
First Solar, Inc. provides solar energy solutions in the United States and internationally. It operates through two segments, Components and Systems. The Components segment designs, manufactures, and sells cadmium telluride solar modules that convert sunlight into electricity. This segment offers its products to solar power systems integrators and operators. The Systems segment provides turn-key photovoltaic solar power systems or solar solutions, such as project development; engineering, procurement, and construction; and operating and maintenance services to utilities, independent power producers, commercial and industrial companies, and other system owners. The company was formerly known as First Solar Holdings, Inc. and changed its name to First Solar, Inc. in 2006. First Solar, Inc. was founded in 1999 and is headquartered in Tempe, Arizona.
​(Summary) (Company) (Chart)
17 September 2017
Price $50.45
1yr Target $52.61
Analysts 14
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain %
Yield %
1yr Tot Return %

P/E ---
PEG ---
Beta ​1.89
​

EPS (ttm) $-4.62
EPS next yr $1.23
Forward P/E 40.95
EPS next 5yr ---
1yr Price Support $---

Market Cap $5.33 Bil
Revenues $2.68 Bil
Earnings $-480.80 Mil
Profit Margin ---

Quick Ratio 6.10
Current Ratio 6.80
Debt/Equity 0.06
1yr RevGR -17.53%
3yr RevGR -3.71%
5yr RevGR 1.30%

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -6.80%
ROE -8.90%
Veritone, Inc., a cloud-based cognitive software company, develops a proprietary artificial intelligence platform for various markets in the United States and internationally. Its cloud-based open platform integrates and orchestrates an ecosystem of cognitive engines to reveal multivariate insights from various amounts of audio, video, and structured data; and incorporates proprietary technology to manage and integrate a range of AI processes to mimic human cognitive functions comprising perception, reasoning, prediction, and problem solving to transform unstructured data into structured data. The company offers media agency services, including media planning and strategy, media buying and placement, campaign messaging, clearance verification and attribution, and custom analytics to manage, deliver, optimize, verify, and quantify advertising campaigns and content distribution for various clients across multiple channels comprising broadcast radio, satellite audio, streaming audio, broadcast and cable television, digital video, and podcasting. It also provides Software-as-a-Service solutions for media owners and broadcasters to automatically index and organize audio and video content to search, discover, and analyze their media for programming and optimization; political organizations to analyze public and private media, conduct research, and provide access to previously inaccessible data; legal professionals to find the critical details of their cases by storing, organizing, and analyzing evidentiary media; and police and other government authorities to organize and gain insight from the large amount of audio, video, and structured data they accumulate on a daily basis, as well as offers solutions for other markets, including commercial security and retail. The company was formerly known as Veritone Delaware, Inc. and changed its name to Veritone, Inc. in July 2014. Veritone, Inc. was founded in 2014 and is headquartered in Newport Beach, California.
​(Summary) (Company) (Chart)
17 September 2017
Price $30.07

1yr Target $18.00
Analysts 4
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain %
Yield %
1yr Tot Return %

P/E ---
PEG ---
Beta ---
​

EPS (ttm) $-4.77
EPS next yr $-2.10
Forward P/E ---
EPS next 5yr 20.00%
1yr Price Support $---

Market Cap $391.21 Mil
Revenues $12.00 Mil
Earnings $-50.00 Mil
Profit Margin ---

Quick Ratio 2.60
Current Ratio 2.60
Debt/Equity 0.00
1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA ---
ROE ---
0 Comments

Best Ideas 10 September 2017

9/10/2017

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect.

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
Corcept Therapeutics discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
(Summary) (Company) (Chart)
10 September 2017
Price $17.26
1yr Target $14.20
Analysts 5
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain -17.73%
Yield 0.00%
1yr Tot Return -17.73%

P/E 86.30
PEG 1.18
Beta 2.07


EPS (ttm) $0.20
EPS next yr $0.69
Forward P/E 25.09
EPS next 5yr 73.20%
1yr Price Support $50.50

Market Cap $1.82 Bil
Revenues $108.70 Mil
Earnings $24.20 Mil
Profit Margin 22.26%

Quick Ratio 3.80
Current Ratio 4.00
Debt/Equity 0.07


1yr RevGR 61.71%
3yr RevGR 97.39%
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 33.00%
ROE 51.40%


Immunomedics, Inc. focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
(Summary) (Company) (Chart)
10 September 2017
Price $11.80
1yr Target $12.50
Analysts 3
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 5.93%
Yield 0.00%
1yr Tot Return 5.93%

P/E ---
PEG ---
Beta 1.59


EPS (ttm) $-1.44
EPS next yr $-0.29
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $1.22 Bil
Revenues $3.10 Mil
Earnings $-153.20 Mil
Profit Margin ---

Quick Ratio 1.30
Current Ratio 1.30
Debt/Equity ---


1yr RevGR -4.40%
3yr RevGR -29.83%
5yr RevGR -37.63%

1yr EarnGR %
3yr EarnGR %
5yr EarnGR %

1yr DivGR %
3yr DivGR %
5yr DivGR %

ROA -198.30%
ROE 182.10%


The Trade Desk, Inc., a technology company, operates a self-service cloud-based platform that enables advertising buyers to create, manage, and optimize data-driven digital advertising campaigns using their own teams in the United States and internationally. Its platform allows clients to manage integrated advertising campaigns across various advertising formats, including display, video, audio, native, and social, as well as on various devices, such as computers, mobile devices, and connected television. The company serves advertising agencies and other service providers for advertisers. The Trade Desk, Inc. was founded in 2009 and is headquartered in Ventura, California.
(Summary) (Company) (Chart)
20 August 2017
Price $56.23
1yr Target $61.25
Analysts 8
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 8.92%
Yield 0.00%
1yr Tot Return 8,92%

P/E 69.16
PEG 2.02
Beta ---
​
EPS (ttm) $0.81
EPS next yr $1.55
Forward P/E 36.23
EPS next 5yr 34.30%
1yr Price Support $53.16

Market Cap $2.29 Bil
Revenues $251.50 Mil
Earnings $35.00 Mil
Profit Margin 13.91%

Quick Ratio 1.70
Current Ratio 1.70
Debt/Equity 0.00
​
1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 7.20%
ROE 20.60%
​
0 Comments

Best Ideas 27 Aug/3 Sep 2017

9/3/2017

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. They're each showing a nice estimated 1yr ROI and increasing earnings. I believe each of these has a greater potential return than analysts currently expect. As with all of my investments, I'll start with a small positions and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington's disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
(Summary) (Company) (Chart)
27 August 2017
Price $10.70
1yr Target $12.60
Analysts 5
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 17.75%
Yield 0.00%
1yr Tot Return 17.75%

P/E ---
PEG ---
Beta 3.12


EPS (ttm) $-0.80
EPS next yr $-0.81
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $926.30 Mil
Revenues $23.40 Mil
Earnings $-57.70 Mil
Profit Margin ---

Quick Ratio 6.10
Current Ratio 6.10
Debt/Equity 0.02
1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -30.70%
ROE -38.50%


Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures. The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. Its CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise, robotic-assisted control of coronary guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force and distributor relationships in the United States and internationally. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. The company is headquartered in Waltham, Massachusetts.
(Summary) (Company) (Chart)
27 August 2017
Price $1.78
1yr Target $2.75
Analysts 2
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 54.49%
Yield 0.00%
1yr Tot Return 54.49%

P/E ---
PEG ---
Beta ---
​
EPS (ttm) $-0.27
EPS next yr $-0.19
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $331.10 Mil
Revenues $4.30 Mil
Earnings $-36.20 Mil
Profit Margin ---

Quick Ratio 4.80
Current Ratio 5.10
Debt/Equity 0.05


1yr RevGR 4.14%
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -116.40%
ROE -162.90%
​
Applied Optoelectronics, Inc. designs, manufactures, and sells fiber-optic networking products primarily for Internet data center, cable television (CATV), and fiber-to-the-home (FTTH) networking end-markets. It offers optical modules, lasers, transmitters and transceivers, and turn-key equipment, as well as headend, node, and distribution equipment. The company sells its products to Internet data center operators, CATV and telecommunications equipment manufacturers, and Internet service providers through its direct and indirect sales channels worldwide. Applied Optoelectronics, Inc. was founded in 1997 and is headquartered in Sugar Land, Texas.
​(Summary) (Company) (Chart)
20 August 2017
Price $64.10
1yr Target $85.67
Analysts 9
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 33.65%
Yield 0.00%
1yr Tot Return 33.65%

P/E 15.24
PEG 1.02
Beta 3.15
​

EPS (ttm) $4.21
EPS next yr $5.75
Forward P/E 11.14
EPS next 5yr 15.00%
1yr Price Support $86.25

Market Cap $1.19 Bil
Revenues $368.60 Mil
Earnings $80.80 Mil
Profit Margin 21.92%

Quick Ratio 2.10
Current Ratio 2.90
Debt/Equity 0.09
1yr RevGR 37.28%
3yr RevGR ---
5yr RevGR ---

1yr EarnGR 170.76%
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 22.70%
ROE 32.40%
0 Comments
    Picture
    Dennis McCain

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.

    Picture
    Top 100 Blogs for Dividend Investors

    Archives

    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Categories

    All

    RSS Feed

Powered by Create your own unique website with customizable templates.